CORT Financial Facts
Loss from operations: 3.07MResearch and development: 7.05M
See Full Income Statement
Total stockholders' equity: 31.25M
Total liabilities and stockholders' equity: 62.93M
See Full Balance Sheet
Corcept Therapeutics (CORT) Earnings
|
Expand Research on CORT
| Next EPS Date | 5/2/24 | EPS Growth Rate | +64.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +17.8% | Revenue Growth Rate | +33.2% |
| Average % Move 1-Wk after EPS | +2.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/2/24 | Q124 | N/A | $0.23 | N/A | N/A | $140.79M | N/A | N/A | N/A | ||
| 2/15/24 | Q423 | $0.28 | $0.27 | +$0.01 | $135.4M | $130.31M | N/A |  | | Details | |
| 11/1/23 | Q323 | $0.28 | $0.22 | +$0.06 | $123.6M | $119.71M | N/A | | | Details | |
| 7/27/23 | Q223 | N/A | $0.15 | N/A | N/A | $109.6M | N/A | N/A | N/A | ||
| 8/2/23 | Q223 | $0.25 | $0.15 | +$0.10 | $117.7M | $109.6M | N/A | | | Details | |
| 5/3/23 | Q123 | $0.14 | $0.19 | -$0.05 | $105.7M | $104.91M | N/A | | | Details | |
| 2/14/23 | Q422 | N/A | $0.24 | N/A | N/A | $105.08M | = | N/A | N/A | ||
| 2/28/23 | Q422 | $0.14 | $0.24 | -$0.10 | $103.1M | $105.08M | N/A | | | Details |
